DK1087993T3 - Fas-peptider og antistoffer til at modulere apoptose - Google Patents

Fas-peptider og antistoffer til at modulere apoptose

Info

Publication number
DK1087993T3
DK1087993T3 DK99931070T DK99931070T DK1087993T3 DK 1087993 T3 DK1087993 T3 DK 1087993T3 DK 99931070 T DK99931070 T DK 99931070T DK 99931070 T DK99931070 T DK 99931070T DK 1087993 T3 DK1087993 T3 DK 1087993T3
Authority
DK
Denmark
Prior art keywords
antibodies
peptides
fas
phas
modulate apoptosis
Prior art date
Application number
DK99931070T
Other languages
Danish (da)
English (en)
Inventor
Francesca Chiodi
Original Assignee
Imed Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813194.9A external-priority patent/GB9813194D0/en
Priority claimed from GBGB9905793.7A external-priority patent/GB9905793D0/en
Application filed by Imed Ab filed Critical Imed Ab
Application granted granted Critical
Publication of DK1087993T3 publication Critical patent/DK1087993T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99931070T 1998-06-18 1999-06-15 Fas-peptider og antistoffer til at modulere apoptose DK1087993T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9813194.9A GB9813194D0 (en) 1998-06-18 1998-06-18 Methods and means for modulating apoptosis
GBGB9905793.7A GB9905793D0 (en) 1998-06-18 1999-03-12 Methods and means for modulating apoptosis
PCT/EP1999/004105 WO1999065935A2 (en) 1998-06-18 1999-06-15 Fas peptides and antibodies for modulating apoptosis

Publications (1)

Publication Number Publication Date
DK1087993T3 true DK1087993T3 (da) 2008-07-14

Family

ID=26313898

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99931070T DK1087993T3 (da) 1998-06-18 1999-06-15 Fas-peptider og antistoffer til at modulere apoptose

Country Status (9)

Country Link
US (1) US6846637B1 (pt)
EP (1) EP1087993B1 (pt)
AT (1) ATE391136T1 (pt)
AU (1) AU4772299A (pt)
DE (1) DE69938451T2 (pt)
DK (1) DK1087993T3 (pt)
ES (1) ES2306515T3 (pt)
PT (1) PT1087993E (pt)
WO (1) WO1999065935A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003233662B2 (en) 2002-05-23 2010-04-01 Trustees Of The University Of Pennsylvania Fas peptide mimetics and uses thereof
WO2004005351A2 (en) 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
CA2522700A1 (en) * 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
WO2005094159A2 (en) * 2003-11-12 2005-10-13 Oncomab Gmbh Methods of identifying neoplasm-specific antibodies and uses thereof
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
US7759077B2 (en) 2005-08-02 2010-07-20 Shariat Shahrokh F Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
EP2101877B1 (en) 2006-12-28 2013-06-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo
EP2318441A2 (en) * 2008-07-14 2011-05-11 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
US20100233157A1 (en) * 2009-03-12 2010-09-16 Osorio Lyda M Human antibodies against human fas and their use
US9540431B2 (en) 2012-07-18 2017-01-10 Apogenix Ag Inhibitors of the CD95 signaling pathway for treatment of MDS
US10053510B2 (en) 2013-05-24 2018-08-21 Promis Neurosciences Inc. FasR antibodies and methods of use
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
WO2015158810A1 (en) * 2014-04-17 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides and uses thereof for reducing cd95-mediated cell motility
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
US11142548B2 (en) 2016-05-10 2021-10-12 Sorbonne Universite Agents that activate CD47 and their use in the treatment of inflammation
BR112021019328A2 (pt) 2019-03-29 2021-11-30 Myst Therapeutics Llc Métodos ex vivo para produzir um produto terapêutico de célula t e composições e métodos relacionados
CA3162703A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
BR112022016490A2 (pt) 2020-02-27 2022-10-11 Myst Therapeutics Llc Métodos para enriquecimento ex vivo e expansão de células t reativas tumorais e composições relacionadas das mesmas

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0511202B1 (en) 1990-01-19 1994-06-01 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
CA2067031C (en) 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
US5891434A (en) 1991-06-17 1999-04-06 Centocor, Inc. Monoclonal antibodies to the APO-1 antigen
US5830469A (en) 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
NZ275711A (en) 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
US5663070A (en) 1993-11-15 1997-09-02 Lxr Biotechnology Inc. Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM
CA2158822C (en) 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
JPH08157500A (ja) * 1994-12-08 1996-06-18 Oriental Yeast Co Ltd Ｆａｓ抗原の定量法
WO1997012632A1 (en) 1995-10-05 1997-04-10 Tkb Associates Limited Partnership Methods for treatment of diseases associated with a deficiency of fas ligand activity
DE19544332C2 (de) * 1995-11-28 1999-07-08 Deutsches Krebsforsch Verfahren zum Nachweis der Expression von CD95 Ligand in Zellen
JP3663243B2 (ja) * 1995-12-14 2005-06-22 株式会社医学生物学研究所 Ｆａｓ抗原の免疫学的測定法及び測定用キット
NO971448L (no) 1996-04-01 1997-10-02 Sankyo Co Rekombinante anti-Fas-antistoffer og DNA for disse
US5912168A (en) * 1996-08-30 1999-06-15 Genesis Research & Development Corporation Limited CD95 regulatory gene sequences
AU736287B2 (en) * 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody
IL123888A0 (en) * 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
AU757961B2 (en) 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
CN1191861C (zh) 1999-05-24 2005-03-09 三共株式会社 含有抗Fas抗体的药物组合物

Also Published As

Publication number Publication date
EP1087993B1 (en) 2008-04-02
DE69938451T2 (de) 2009-04-09
PT1087993E (pt) 2008-07-04
WO1999065935A2 (en) 1999-12-23
EP1087993A1 (en) 2001-04-04
AU4772299A (en) 2000-01-05
ES2306515T3 (es) 2008-11-01
WO1999065935A3 (en) 2003-04-17
ATE391136T1 (de) 2008-04-15
US6846637B1 (en) 2005-01-25
DE69938451D1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
DK1087993T3 (da) Fas-peptider og antistoffer til at modulere apoptose
HUP0400951A2 (hu) Egy tumornekrózis faktorral rokon apoptózis indikáló ligandum receptorára specifikus antitest és alkalmazásai
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
BR9809387A (pt) Anticorpos anti-vegf
DE69840966D1 (de) Homolog NL6 des Tie Rezeptor Tyrosinekinase Liganden
EP1137658A4 (en) TECHNIQUES FOR MODULATING THE EXPRESSION OF CELL ADHESION MOLECULES INDUCED BY TUMOR NECROSIS FACTOR- $ g (a)
DK1606317T3 (da) Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation
PT2305715T (pt) Anticorpo monoclonal para a proteína de ligação a osteoprotegerina
ATE382053T1 (de) System zur antikörperexpression und- synthese
IL207146A0 (en) Antibodies capable of competing with anti-il-22ra monoclonal antibodies
TW200635946A (en) Binding proteins specific for human matriptase
WO2004048544A3 (en) Ca ix-specific inhibitors
WO2000001813A3 (en) Peptide inhibitors of androgen-independent activation of androgen receptor
WO2002078598A3 (en) Peptides and antibodies to muc 1 proteins
WO2002065134A3 (en) Modulators of p53-p300 interactions and screening methods therefor
EP1517144A3 (en) Method of identifying an antibody binding to and modulating the activity of a human vanilloid receptor
HUP0402496A2 (hu) Módosított polipeptidek
BR0308401A (pt) Anticorpo humano anti-hfasl isolado, ou porção de ligação de antìgeno do mesmo, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para inibir as atividades de hfasl, e de fasl, e para tratar ou prevenir um distúrbio no qual a atividade de fasl é prejudicial, composição farmacêutica, e, uso de anticorpo ou de fragmento.
ATE513040T1 (de) Zinkfingerdomänenbibliotheken
SE0000675D0 (sv) Monoclonal antibodies
MXPA02011002A (es) Oligopeptidos para promover el crecimiento del cabello.
WO2004012673A3 (en) Methods and reagents relating to inflammation and apoptosis
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
ATE240349T1 (de) Peptide zur inhibierung von hpv e6-proteinen